Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 28;6(3):BJGPO.2022.0001.
doi: 10.3399/BJGPO.2022.0001. Print 2022 Sep.

Concerns regarding tablet splitting: a systematic review

Aanchal K Saran  1 , Natalie A Holden  2 , Scott R Garrison
Affiliations

Concerns regarding tablet splitting: a systematic review

Aanchal K Saran et al. BJGP Open. .

Abstract

Background: Tablet splitting can provide dose flexibility and cost savings; however, pharmaceutical representatives typically discourage the practice.

Aim: To identify and summarise all published concerns related to tablet splitting and to present the experimental evidence that investigates those concerns.

Design & setting: Systematic review and qualitative synthesis of tablet-splitting concerns and evidence.

Method: Medline and EMBASE databases were searched over all years of publication for articles in English discussing the splitting of tablets. Eligible articles included original research, narrative reviews, systematic reviews, and expert opinion.

Results: After removing duplicates, 1837 potentially relevant articles underwent dual review, whereupon 1612 articles were excluded based on title and abstract. After examination of 225 full texts, 138 articles were included (one systematic review, four narrative reviews, 101 original research articles, and 32 opinion articles). The described concerns included difficulty breaking tablets, loss of mass, weight variability, chemical instability, overly rapid dosing if sustained-release medications are split, non-compliance, and patient confusion resulting in medication errors. No substantive evidence was found to support concerns regarding loss of mass, weight variability, chemical instability, or non-compliance. Evidence does support some older adults struggling to split tablets without tablet splitters, and the inappropriateness of splitting sustained-release preparations, given the potential for alteration of the rate of drug release for some products.

Conclusion: With the exception of sustained-release tablets, which should not be split, and excepting those older people who may struggle to split tablets based on physical limitations, there is little evidence to support tablet-splitting concerns.

Keywords: cost savings; delayed-action preparations; dose-reduction; geriatric prescribing; medication errors; pill-splitting; tablets.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Study flow diagram
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cohen JS. Tablet splitting: imperfect perhaps, but better than excessive dosing. J Am Pharm Assoc (Wash) 2002; 42 (2):160–162. doi: 10.1331/108658002763508443. - DOI - PubMed
    1. Morreale A. Pill-splitting: correctly used, it can benefit patients and serve society. Drug Topics. 2011; 155 (8):14
    1. Cohen CI, Cohen SI. Potential cost savings from pill splitting of newer psychotropic medications. Psychiatr Serv. 2000; 51 (4):527–529. doi: 10.1176/appi.ps.51.4.527. - DOI - PubMed
    1. Fahelelbom KMS, Al-Tabakha MMM, Eissa NAM, Javadi J. Evaluation of certain pharmaceutical quality attributes of lisinopril split tablets. Sci Pharm. 2016; 84 (4):646–653. doi: 10.3390/scipharm84040646. - DOI - PMC - PubMed
    1. Carey H, Fondriest M. Cost-savings from an antipsychotic tablet-splitting program. P T. 2017; 42 (6):384–393. - PMC - PubMed

LinkOut - more resources